---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026247"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:20:59.295968+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharmaceuticals prices $7.0M public offering of ADSs and warrants; amends prior warrants

## Summary
- Gross proceeds ~$7.0M from offering of 4.95M ADSs at $1.00/ADS and pre-funded warrants for 2.05M ADSs at $0.9999, each with common warrants.
- Existing warrants from Aug 2022 amended: exercise price reduced from $5.00 to $1.10 per ADS, term extended to Feb 24, 2028.
- Offering closed Feb 24, 2023; net proceeds for general corporate purposes.
- Placement agents: A.G.P./Alliance Global Partners (lead), Maxim Group, Aegis Capital; fees 7% cash plus 1% expense allowance.

## SEC filing metadata
- accession: 0001104659-23-026247
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/0001104659-23-026247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/tm237968d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026247
- JSON: https://secwatch.observer/filing/0001104659-23-026247.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026247.txt

## Key facts
- Material Agreements
  Quoin Pharmaceuticals, Ltd. entered into Securities Purchase Agreement with certain investors valued at approximately $7 million (effective 2023-02-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: approximately $7 million
  - Effective: 2023-02-22
  source text: On February 22, 2023, Quoin Pharmaceuticals Ltd. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) of 24,750,000,000 ordinary shares represented by 4,950,000 American Depositary Shares (“ADSs”) at a purchase price of $1.00 per ADS
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/0001104659-23-026247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.